Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Your genes play a huge role in what makes and shapes your entire existence. Since you inherit your genes from your parents, ...

Cell-engineering company, MaxCyte, Inc., announced it will acquire SeQure Dx, which focuses on editing assessment services for cell and gene therapies, for $4.5 million. The all-cash deal includes ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

Ugandans with chronic diseases who had taken long without being treated or had lost hope of getting the next lease of life can afford a smile following the launch of stem cell therapy.The Joint ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.